Anti-TNF-α have revolutionized the treatment of inflammatory bowel disease, but a
significant proportion of patients do not respond or lose response over time after treatment …

The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the
treatment of inflammatory bowel disease (IBD). However, some patients experience primary …

The management of Crohn's disease and ulcerative colitis has become increasingly
complex. With the current utilization of immunosuppressive therapies earlier in the disease …

Vedolizumab is a monoclonal antibody to the α4β7 integrin that selectively reduces
intestinal lymphocyte trafficking, thereby providing a safe and effective treatment option for …

Background: Vedolizumab is a humanized immunoglobulin G1 monoclonal antibody, which
binds to α4β7 integrin on T lymphocytes, thus disturbing the interaction with mucosal …

Inflammatory bowel disease (IBD) is an important cause of morbidity and mortality for
millions of patients worldwide. Current treatment options include corticosteroids, 5 …

Anti-TNF agents are highly effective in treating inflammatory bowel diseases, but loss of
response and side-effects leading to drug interruption are often reported. New molecules …

Two decades ago, the first reports of the use of monoclonal antibodies targeting tumour-
necrosis factor α heralded a revolution in treatment options for moderate to severe Crohn's …

Background Vedolizumab, a gut‐selective α4β7 integrin antibody, is approved for
moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Aim To report …

BF Most drugs used to treat inflammatory bowel disease (IBD) are systemically
immunosuppressive, which means that they affect the immune system throughout the entire …